A 52 ‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
LUTS: Lower Urinary Tract Symptoms, EarlyView.
CONCLUSION: The status of executive function and working memory, as well as the age and severity of the pathological symptoms of lower urinary tract should be taken into account when predicting the risks of rejecting BPH and OAB treatment in elderly patients. PMID: 31560296 [PubMed - as supplied by publisher]
Condition: Overactive Bladder Intervention: Drug: Vibegron Sponsor: Urovant Sciences GmbH Enrolling by invitation
CONCLUSIONS: Our results demonstrate no difference in the etiology of nocturia between black and white males. Accordingly, race should not play a role in the evaluation of patients seeking treatment for nocturia. PMID: 31180307 [PubMed - in process]
Condition: Overactive Bladder Interventions: Drug: Vibegron; Drug: Placebo Sponsor: Urovant Sciences GmbH Recruiting